Atrial Fibrillation and HFpEF

Atrial Fibrillation and HFpEF: Diagnostic Challenges and Therapeutic Opportunities

Introduction

Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) frequently coexist, particularly in elderly patients with multiple comorbidities. Each condition can precipitate or exacerbate the other, creating a complex clinical syndrome associated with high morbidity, recurrent hospitalizations, and increased mortality.

---

Pathophysiological Interplay

AF and HFpEF share common risk factors:

Hypertension

Diabetes mellitus

Obesity

Aging

Chronic kidney disease

Key mechanisms linking AF and HFpEF:

Left atrial (LA) remodeling: Elevated LV filling pressures → LA dilation → AF substrate

Loss of atrial kick: Reduces LV filling → worsens HFpEF symptoms

Tachycardia-induced cardiomyopathy: Persistent AF → diastolic dysfunction

Fibrosis and inflammation: Shared substrate driving both conditions

---

Diagnostic Challenges

1. Symptom Overlap

Dyspnea, fatigue, and exercise intolerance are common to both

AF may mask or mimic HFpEF exacerbation

2. Limitations of Echocardiography

Assessment of diastolic dysfunction becomes difficult in AF due to:

Beat-to-beat variability

Absence of A-wave

E/e′ ratio may be unreliable

3. Natriuretic Peptides

BNP/NT-proBNP are elevated in both AF and HF

AF independently raises natriuretic peptide levels → reduced specificity

4. Underdiagnosis of HFpEF in AF

Many AF patients with dyspnea are labeled as “AF-related symptoms”

HFpEF often remains unrecognized unless specifically evaluated

5. Role of Advanced Testing

Diastolic stress testing (exercise echo)

Invasive hemodynamics (gold standard in unclear cases)

---

Clinical Clues Suggesting HFpEF in AF

Persistent dyspnea despite rate control

Elevated natriuretic peptides disproportionate to AF burden

LA enlargement and LV hypertrophy

Pulmonary hypertension on echo

---

Therapeutic Opportunities

---

1. Rate vs Rhythm Control

Rate Control

Beta-blockers

Non-dihydropyridine calcium channel blockers

Digoxin (selected patients)

Limitation:

Does not restore atrial contribution → symptoms may persist

---

Rhythm Control (Increasingly Favored)

Antiarrhythmic drugs (e.g., amiodarone, flecainide in selected cases)

Electrical cardioversion

Catheter ablation

Why rhythm control matters in HFpEF:

Restores atrial kick → improves LV filling

Reduces LA pressure

Improves exercise capacity

Evidence trend: Early rhythm control improves outcomes in selected patients

---

2. Catheter Ablation

Emerging as a key strategy in AF + HFpEF

Benefits:

Symptom improvement

Reduced hospitalizations

Possible reverse remodeling

Best candidates:

Symptomatic AF

Early-stage HFpEF

Less advanced atrial fibrosis

---

3. HFpEF-Directed Therapy

SGLT2 Inhibitors (Game-Changer)

Empagliflozin / Dapagliflozin

Reduce HF hospitalizations regardless of diabetes

Diuretics

Symptom relief (volume management)

Blood Pressure Control

Strict control improves outcomes

Mineralocorticoid Receptor Antagonists

Selected benefit in some HFpEF populations

---

4. Risk Factor Modification

Critical and often underestimated:

Weight loss (especially in obese patients)

Treatment of obstructive sleep apnea

Glycemic control

Aggressive hypertension management

Exercise training

---

5. Anticoagulation

Stroke risk remains high

Use CHA₂DS₂-VASc score

Direct oral anticoagulants (DOACs) preferred unless contraindicated

---

Emerging Concepts

Atrial cardiomyopathy as a primary driver

Early AF ablation to prevent HFpEF progression

Role of fibrosis imaging (cardiac MRI)

Personalized phenotyping of HFpEF

---

Key Takeaways

AF and HFpEF frequently coexist and worsen each other

Diagnosis is challenging due to overlapping symptoms and test limitations

Rhythm control—especially early—may offer significant benefits

SGLT2 inhibitors are foundational in HFpEF management

Risk factor modification is essential for long-term success

---

Conclusion

The coexistence of AF and HFpEF represents a modern cardiovascular epidemic. A high index of suspicion, careful diagnostic evaluation, and an integrated therapeutic approach—combining rhythm control, HFpEF therapy, and aggressive risk factor management—are essential to improving patient outcomes.

---

Drmusmanjaved.com